Changchun High‑Tech Industry Group Co. Ltd. Announces Strategic Licensing Deal with Yarrow Bioscience, Inc.
Changchun High‑Tech Industry Group Co. Ltd. (stock code 000661) reported a 5.04 % intraday gain, rising to 96.7 CNY on December 16, 2025. The rally followed the company’s disclosure that its subsidiary, Sai Zeng Medical, has signed an exclusive licensing agreement with Yarrow Bioscience, Inc. for the GenSci 098 injectable product line (GenSci 098).
Deal Structure
| Item | Detail |
|---|---|
| Licensor | Sai Zeng Medical (subsidiary of Changchun High‑Tech) |
| Licensee | Yarrow Bioscience, Inc. |
| Product | GenSci 098 injection, a clinical‑stage therapy for Graves’ disease and thyroid eye disease |
| Up‑front Payment | US$120 million |
| Milestone Payments | Potential to receive up to US$1.365 billion in development, regulatory, and commercial milestones |
| Sales‑Based Incentive | Yarrow will earn a royalty of more than 10 % of net sales once the product is commercialised |
| Strategic Alignment | The partnership aligns with Yarrow’s global strategy to lead the development of anti‑TSHR monoclonal antibodies outside of China |
The agreement was approved by Changchun High‑Tech’s eleventh‑session, fifteenth‑meeting board of directors on December 15, 2025, and was subsequently announced by the company.
Market Reaction
- Intraday Performance – The stock rose more than 7 % during the trading session, reaching 96.7 CNY by the close of the day.
- Sector Context – The news arrived amid a broader market correction, with the Shanghai Composite, Shenzhen Component, and ChiNext indices all experiencing declines. Nevertheless, several companies, including Changchun High‑Tech, issued positive corporate updates that helped mitigate the overall downturn.
Company Profile
- Sector: Health Care
- Industry: Pharmaceuticals
- Primary Exchange: Shenzhen Stock Exchange
- Market Capitalisation: 37 090 000 000 CNY
- Price‑Earnings Ratio: 38.56
- 52‑Week Range: 83 – 141.77 CNY
- Recent Close (2025‑12‑14): 92.06 CNY
Changchun High‑Tech operates through subsidiaries that manufacture biopharmaceuticals, traditional Chinese medicines, electrolytic condensers, and manage real‑estate assets. The GenSci 098 licensing deal represents a significant step in the company’s strategy to expand its global pharmaceutical footprint and generate new revenue streams through international partnerships.
